| Tekturna (aliskiren) / PDL |
2009-016077-14: Role of ALiskiren, a direct renin inhibitor, in preventing atrial Fibrillation in patients with a pacemaker; RALFEteisvärinäkuorman määritys sydämentahdistimella aliskireenihoidossa |
|
|
| Ongoing | 4 | 70 | Europe | Rasilez, Rasilez | Mika Lehto | Patients who have a pacemaker due to sinus node disease and paroxysmal atrial fibrillation. | | | | |
2011-002587-24: Effect of Aliskiren drug in patients with high blood pressure Effetto del farmaco Aliskiren in pazienti con pressione alta |
|
|
| Ongoing | 4 | 42 | Europe | ENALAPRIL S.G.*28CPR 5MG, RASILEZ*56CPR RIV 150MG, ENALAPRIL S.G.*28CPR 5MG, RASILEZ*56CPR RIV 150MG | FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR, Novartis | dysfunction of coronary microcirculation in arterial hypertension disfunzione del microcircolo coronarico nell\'ipertensione arteriosa | | | | |
NCT06718062: Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia |
|
|
| Completed | 4 | 66 | RoW | Aliskiren, Losartan | Hansung University | Hypertension,Essential, Hyperuricemia | 05/24 | 10/24 | | |
ChiCTR1900028215: Treatment of Obstructive Sleep Apnea Syndrome Related Hypertension with Aliskiren (Rasilez): a Single Center, One-Armed, Open-Label Clinical Trial. |
|
|
| Recruiting | 4 | 30 | | Aliskiren | Beijing Anzhen Hospital, Capital Medical University; Beijing Anzhen Hospital, Zhaoke Pharmaceutical (Hefei) Co. Ltd. | Hypertension in Obstructive Sleep Apnea Syndrome(OSAS) patients | | | | |
ALPINE, NCT01123629: Aleskiren Effect on Plaque Progression Using 3-dimensional Magnetic Resonance Imaging (3D MRI) |
|
|
| Recruiting | 3 | 70 | US | Aliskiren, Tekturna, placebo | Ohio State University | Atherosclerosis | 10/11 | 05/12 | | |
2007-005401-22: Effect of Aliskiren on Muscle Sympathetic Nerve Activity in hypertensive patients with chronic kidney disease |
|
|
| Ongoing | 3 | 20 | Europe | Aliskiren (Rasilez), ATC-code: C09XA02, | University Medical Center Utrecht | Hypertension and chronic kidney disease | | | | |
2010-021987-13: Renal Hemodynamic Effects of ALiskiren (rasilez) in comparison to ramipril (Tritrace) in patients with overweigHt/obeSiTy and UntreateD hYpertension: The renal HEALTH-STUDY |
|
|
| Ongoing | 3 | 16 | Europe | Rasilez, tritace, EU/1/07/405/011-020, RVG 13297, aliskiren, ramipril, aliskiren, ramipril | University Medical Center Groningen | Glomerular hypertension | | | | |
2008-007881-45: A double-blind, placebo-controlled, randomized trial investigating the safety and efficacy of Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction |
|
|
| Ongoing | 2 | 100 | Europe | Aliskiren, SPP100, Rasilez, Rasilez | University Medical Center Groningen | Patients with chronic heart failure and reduced glomerular filtration rate. | | | | |
2009-010608-27: A prospective cohort study to investigate the use of alfa V beta 3 integrin scintigraphic imaging with 99mTC-NC100692 to predict scar formation and heart failure after myocardial infarction in patients. |
|
|
| Ongoing | 2 | 123 | Europe | Telmisartan, Aliskiren, 144701-48-4, 173334-57-1, Telmisartan, Aliskiren, Telmisartan, Aliskiren | MUMC+ | Myocardial infarction | | | | |
| Recruiting | 2 | 30 | Europe | Aliskiren, Enalapril | Region Skane | C3 Glomerulopathy, Membranoproliferative Glomerulonephritis, Complement Abnormality, Dense Deposit Disease, C3 Glomerulonephritis | 12/29 | 12/29 | | |
2012-000855-15: Study to determine bioavailablity of 300 mg aliskiren mini-tablets vs 300 mg aliskiren market tablet. |
|
|
| | 1 | | NA | Aliskiren, SPP100, Rasilez, Rasilez | Novartis Pharma Services AG, Novartis Pharma Services AG | Hypertension | | | | |
ChiCTR1800017739: A study for the effect of aliskiren on endothelial progenitor cells in patients with hypertension |
|
|
| Recruiting | N/A | 40 | | drug(aliskiren) ;Nil | The First Affiliated Hospital, Sun Yat-sen University; The First Affiliated Hospital, Sun Yat-sen University, the project of Zhu Jiang Science and Technology new star of Guangzhou City | hypertension | | | | |
ChiCTR2000032314: A randomized clinical trial for the efficacy and safety of Aliskiren and Nifedipine in novel coronavirus pneumonia (COVID-19) patients with hypertension |
|
|
| Recruiting | N/A | 242 | | Aliskiren with Standard Care ;Nifedipine with Standard Care | West China Hospital, Sichuan University; West China Hospital, Sichuan University, West China Hospital, Sichuan University | Novel Coronavirus Pneumonia (COVID-19)N; hypertension | | | | |
| IONIS-AGT-LRx / Ionis |
ASTRAAS, NCT04714320: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure |
|
|
| Completed | 2 | 160 | Canada, US | IONIS-AGT-LRx, ISIS 757456, Placebo | Ionis Pharmaceuticals, Inc. | Hypertension | 09/22 | 09/22 | | |
| Completed | 2 | 72 | Europe, US | IONIS-AGT-LRx, ISIS 757456, Placebo | Ionis Pharmaceuticals, Inc. | Chronic Heart Failure With Reduced Ejection Fraction | 10/22 | 01/23 | | |
| SPH3127 / Shanghai Pharma |
SPH3127-301, NCT05359068: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension |
|
|
| Completed | 3 | 957 | RoW | SPH3127 tablet, Valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Essential Hypertension | 12/23 | 12/23 | | |
NCT05019742: Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis |
|
|
| Recruiting | 2 | 30 | US | SPH3127, Placebo | Shanghai Pharma Biotherapeutics USA Inc. | Ulcerative Colitis | 12/25 | 12/25 | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 06/25 | 06/25 | | |
NCT05770609: A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis |
|
|
| Recruiting | 2 | 108 | RoW | SPH3127 Tablets with Dose A, SPH3127 Tablets with Dose B, SPH3127 Tablets placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Mild to Moderate Ulcerative Colitis | 02/25 | 02/25 | | |
